<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639505</url>
  </required_header>
  <id_info>
    <org_study_id>P2020004</org_study_id>
    <nct_id>NCT04639505</nct_id>
  </id_info>
  <brief_title>Predictive Value of New AMH Test Method for Ovarian Response</brief_title>
  <official_title>Predictive Value of New AMH Test Method for Ovarian Response in Patients With IVF/ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In China, the incidence of infertility is about 15%, and patients need to use assisted&#xD;
      reproductive technology (ART) to obtain pregnancy. It is particularly important to accurately&#xD;
      predict the patient's ovarian response before initiating controlled ovulation&#xD;
      hyperstimulation (COH). At present, the commonly used AMH detection method is enzyme-linked&#xD;
      immunoassay (ELISA), and it has obtained the normal reference range for ovarian response. In&#xD;
      recent years, with the development of detection technology, chemiluminescence&#xD;
      immunoassay（CLIA） detection reagents have been successively used for the detection of AMH.&#xD;
      However, there are few studies on the comparison of these two detection methods. The&#xD;
      predictive value of the new method on ovarian response was lack. Therefore, by comparing the&#xD;
      two methods of ELISA and CLIA detection of AMH levels in this study, the predictive value of&#xD;
      poor ovarian response (the number of retrieved oocyte ≤ 3) and high response (the number of&#xD;
      retrieved oocyte ≥ 15) in IVF/ICSI stimulation cycle was analyzed. In order to provide more&#xD;
      reference basis for individualized COH, the AMH cutoff value of low and high ovarian response&#xD;
      by the new method predicts was analyzed. At the same time, the prediction value of the two&#xD;
      methods is compared to determine whether the new CLIA is suitable for clinical application.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the AMH（CLIA） cutoff value of low and high ovarian response</measure>
    <time_frame>the day of oocytes retrieved，about three months after AMH test</time_frame>
    <description>the poor ovarian response :the number of retrieved oocyte ≤ 3,the high ovarian response :the number of retrieved oocyte ≥ 15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>34-36 hours after hCG trigger，about three months after AMH test</time_frame>
    <description>the number of oocytes retrieved after hCG trigger</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the serum AMH level</measure>
    <time_frame>any day of the menstrual cycle, about three months after study starting</time_frame>
    <description>anti-muller hormone</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Infertility</condition>
  <condition>AMH</condition>
  <arm_group>
    <arm_group_label>ELISA</arm_group_label>
    <description>ELISA kit detecting the serum AMH level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemiluminescence</arm_group_label>
    <description>CLIA method detecting the serum AMH level</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ELISA</intervention_name>
    <description>ELISA kit detecting the serum AMH level</description>
    <arm_group_label>ELISA</arm_group_label>
    <other_name>experimental group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Chemiluminescence</intervention_name>
    <description>CLIA method detecting the serum AMH level</description>
    <arm_group_label>Chemiluminescence</arm_group_label>
    <other_name>control group</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        infertility females&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The first IVF/ICSI COH cycle;&#xD;
&#xD;
          -  the causes of infertility :fallopian tube factors and/or male factors;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Endometriosis;&#xD;
&#xD;
          -  PCOS;&#xD;
&#xD;
          -  Adenomyosis;&#xD;
&#xD;
          -  PGT cycle because of the female chromosome abnormality or genetic abnormality;&#xD;
&#xD;
          -  FET cycle;&#xD;
&#xD;
          -  Malignant tumor patient.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Reproductive &amp; Genetic Hospital of CITIC-XIANGYA</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yuan li, PhD</last_name>
      <phone>86-731-82355100</phone>
      <email>1002251255@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

